SA
Log In
LEGN
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
18 analysts·Moderate coverage
72
Score
16 Buy (89%)2 Hold (11%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1689%
Hold
211%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$24.00
+1.7%
Consensus
$62.00
+162.8%
Bull
$75.00
+217.9%
12-Month Target Range18 analysts
$24.00$62.00$75.00
Current $23.59Consensus
Current Price
$23.59
Upside to Consensus
$38.41

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+27.19%
EPS+307.25%
FY2028
Rev+16.76%
EPS+74.91%
FY2029
Rev+19.22%
EPS+13.33%

Earnings Surprises

Recent Analyst Actions

Mar 11, 2026Morgan Stanley
Legend Biotech price target lowered to $49 from $50 at Morgan Stanley
Target:$49.00
+141.7%from $20.27
Mar 11, 2026RBC Capital
Legend Biotech price target lowered to $62 from $66 at RBC Capital
Target:$62.00
+205.9%from $20.27
Mar 10, 2026Truist Financial
Truist Securities Reiterates Buy Rating on Legend Biotech Corp. (LEGN): "infer from comments that Raritan's full manufacturing slot capacity approved"
Target:$70.00
+257.9%from $19.56
Mar 10, 2026Jefferies
Jefferies Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
Target:$69.00
+252.8%from $19.56
Feb 12, 2026Redburn Partners
Legend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
Target:$24.00
+29.4%from $18.54
Jan 22, 2026H.C. Wainwright
Legend Biotech price target lowered to $50 from $60 at H.C. Wainwright
Target:$50.00
+140.8%from $20.76
Jan 22, 2026Jefferies
TD Cowen Downgrades Legend Biotech Corp. (LEGN) to Hold
Target:$21.00
+1.2%from $20.76
Jan 20, 2026RBC Capital
FDA draft guidance favorable for Legend Biotech, says RBC Capital
Target:$66.00
+180.5%from $23.53
Jan 7, 2026Oppenheimer
Legend Biotech initiated with an Outperform at Oppenheimer
Target:$75.00
+241.5%from $21.96
Dec 17, 2025Cantor Fitzgerald
Legend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald
Target:$74.00
+241.8%from $21.65
Dec 12, 2025Morgan Stanley
Legend Biotech price target lowered to $50 from $83 at Morgan Stanley
Target:$50.00
+120.5%from $22.68
Dec 8, 2025RBC Capital
RBC Capital on Legend Biotech Corp. (LEGN): 'We Would Be Buyers'
Target:$74.00
+201.3%from $24.56
Dec 8, 2025UBS
Legend Biotech price target lowered to $48 from $54 at UBS
Target:$48.00
+70.6%from $28.13
Oct 17, 2025Johnson Rice
Legend Biotech price target lowered to $60 from $75 at H.C. Wainwright
Target:$60.00
+85.4%from $32.36
Jul 2, 2025UBS
Legend Biotech price target lowered to $54 from $60 at UBS
Target:$54.00
+50.4%from $35.91
Mar 12, 2025H.C. Wainwright
Legend Biotech price target raised to $75 from $73 at H.C. Wainwright
Target:$75.00
+101.7%from $37.19
Nov 13, 2024Cantor Fitzgerald
Legend Biotech Corp. (LEGN) PT Raised to $83 at Cantor Fitzgerald
Target:$83.00
+48.5%from $55.90
Oct 15, 2024BTIG
BTIG Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
Target:$91.00
+102.6%from $44.91
Oct 15, 2024Johnson Rice
Legend Biotech weakness a buying opportunity, says Barclays
Target:$94.00
+107.8%from $45.24
Oct 15, 2024Barclays
Barclays Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
Target:$94.00
+109.3%from $44.91
Oct 8, 2024Redburn Partners
Legend Biotech initiated with a Buy at Redburn Atlantic
Target:$86.00
+73.5%from $49.58
Jun 17, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
Target:$90.00
+114.3%from $42.00
Jun 17, 2024Truist Financial
Legend Biotech initiated with a Buy at Truist
Target:$88.00
+107.3%from $42.45
May 23, 2024Deutsche Bank
Deutsche Bank Starts Legend Biotech Corp. (LEGN) at Buy
Target:$60.00
+49.9%from $40.04
May 17, 2024Morgan Stanley
Legend Biotech Corp. (LEGN) PT Lowered to $82 at Morgan Stanley
Target:$82.00
+76.8%from $46.37

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance